ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ACHC / earnings
CLOV (38) CELC (32) FTRE (35) CDNA (69) ⌘ Pro Terminal →

Acadia Healthcare Company Inc. (ACHC) Next Earnings Date & Expected ±8.2% Move

$29.96 +1.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.99

Acadia Healthcare Company Inc. (ACHC) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $2.74B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACHC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Acadia Healthcare Company Inc. (NASDAQ: ACHC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $29.96 (+1.70% 1D, market cap $2.74B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ACHC ranks #602 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACHC compare to CLOV and CELC in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), ACHC carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -24.8%. By comparison, CLOV (Clover Health Investments Corp. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.3%, cap $2.43B) and CELC (Celcuity Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.39B). Among the 5-stock peer group, ACHC leads on earnings multiple (N/A) while CDNA leads on capital efficiency (-8.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACHC?
▼

Per ACHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520697), Acadia Healthcare Company Inc. generated $3.31B in revenue (+5.0% YoY), -$1.10B in net income, and -$439.9M in free cash flow against $5.53B in total assets and $2.47B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $30.00 (+0.12%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Cash (5)Whales (13)SEC (5)Macro (8)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$38 Bull$27 Base$21 Bear
📬 FREE ACHC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACHC)Realized 20D OHLCV Swing Band: ±8.2%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY ACHC SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (35% of score)

20D Institutional Volume Accumulation (±8.2% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 76% of 52W Range • RSI-14 at 47.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$30.23+4% Next Q
Q2 (-2Q)
42
Grade D$31.43-4.9% Next Q
Q3 (-1Q)
40
Grade D$29.90+0.2% Next Q
Current
37
Grade D-$29.96-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACHC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACHC currently carries a cautious 37/100 (D-) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($29.13) and Max Pain ($31.46) forces dealer call-delta covering toward $37.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACHC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±8.2% Swing Band

±$2.46 Expected Swing
$27.50 (-8.2%)Spot $29.96$32.42 (+8.2%)
MODEL EARNINGS SETUP GAUGE

ACHC Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $-11.84 • YoY Revenue Growth: 5%

Model Bullish Setup (37/100)Model Risk Weight (63/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$3.31B-$1.10B-$439.9M52%
FY 20242024-12-31$3.15B$255.6M-$560.7M52%
FY 20232023-12-31$2.93B-$21.7M$330.5M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACHC)

  • ✓Walkthrough of ACHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ACHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.20%📐 HORIZONTAL RANGE
2026-11-02O $29.51H $29.96L $29.46C $29.96VOL 2.74M
RES: $32.34SUP: $26.80SMA50: $29.13SMA200: $25.97
$36.91$32.43$27.95$23.46$18.98RES $32.34SUP $26.80$29.962026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACHC Butterfly Map → + Track ACHC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
14.6%/yr Implied 5Y Growth

vs. +5.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACHC)

Health Care Rank #602 of 1016 ⚔️ CLOV vs ACHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACHC vs. CLOV, CELC, FTRE, CDNA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Acadia Healthcare Company Inc. (ACHC) ranks #602 by composite RQD confidence (37/100, grade D-) and #215 by equity capitalization ($2.74B). Within this direct 5-issuer industry benchmark cohort, ACHC leads on earnings valuation at N/A trailing P/E, while CDNA leads on capital efficiency and profitability with -8.2% ROIC and — gross margin. CDNA currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ACHC at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ACHC ACTIVE
Acadia Healthcare Company Inc.
D- 37/100 — — -24.8% +1.70% $2.74B Benchmark Subject
CLOV
Clover Health Investments Corp. (Class A)
D- 38/100 — — -29.3% -2.62% $2.43B /clov-vs-achc →
CELC
Celcuity Inc.
E 32/100 — — -35.0% -0.24% $3.39B /celc-vs-achc →
FTRE
Fortrea Holdings Inc.
D- 35/100 — — -35.0% -7.97% $2.20B /ftre-vs-achc →
CDNA
CareDx Inc.
C+ 69/100 — — -8.2% +22.22% $3.70B /cdna-vs-achc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001520697

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acadia Healthcare Company Inc. (ACHC) reported GAAP revenue of $3.31B (+5.0% vs. FY2024 revenue of $3.15B , and +13.1% cumulative change since FY2023) , GAAP net income of -$1.10B, operating cash flow of $131.9M, and free cash flow of -$439.9M (+21.5% YoY). On the balance sheet, ACHC closed FY2025 with $5.53B in total assets against $2.47B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.31B -$1.10B $131.9M -$439.9M $5.53B $2.47B
FY2024 (FY) 2024-12-31 $3.15B $255.6M $129.7M -$560.7M $5.96B $1.88B
FY2023 (FY) 2023-12-31 $2.93B -$21.7M $462.3M $330.5M $3.51B $822.4M

3. ACHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Acadia Healthcare Company Inc. (NASDAQ: ACHC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $29.96 (+1.70% 1D, market cap $2.74B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ACHC ranks #602 in composite RQD confidence.

How does ACHC compare to CLOV and CELC in the Health Care sector?

Within the Health Care sector (Medical Specialities), ACHC carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -24.8%. By comparison, CLOV (Clover Health Investments Corp. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.3%, cap $2.43B) and CELC (Celcuity Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.39B). Among the 5-stock peer group, ACHC leads on earnings multiple (N/A) while CDNA leads on capital efficiency (-8.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACHC?

Per ACHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520697), Acadia Healthcare Company Inc. generated $3.31B in revenue (+5.0% YoY), -$1.10B in net income, and -$439.9M in free cash flow against $5.53B in total assets and $2.47B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACHC trading relative to its 50-day, 200-day, and 52-week technical levels?

ACHC last traded at $29.96 (+1.70% on volume of 2,575,638 shares), positioning the stock +2.85% above its 50-day simple moving average ($29.13) and +15.36% above its 200-day simple moving average ($25.97). Across its 52-week range of $11.43 to $35.83, ACHC sits at the 75.9% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($27.50 to $32.42).

ACHC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ACHC's next earnings date?

Based on SEC filing cadence, Acadia Healthcare Company Inc. (ACHC)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ACHC stock expected to move on earnings?

Volatility modeling currently projects a ±8.2% event move for ACHC, spanning a range between $27.5 and $32.42.

Direct Sub-Reports: ACHC RQD Cockpit ACHC 12M Forecast ACHC Earnings & Move ACHC Dividends & DRIP ACHC Insiders & 13F ACHC Whale Options ACHC Profit Sankey ACHC News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ACHC — Acadia Healthcare Company Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:25:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ACHC scores 37 out of 100, a letter grade of D-, and the verdict label is "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

  • Fundamental Cash Engine (5 / 20): Per the RQD rating, ROIC is -24.8% and FCF yield is -16.04%. Investor implication: the business is currently not generating economic returns on invested capital or free cash flow relative to its market value, so any upside case depends on a future operating turnaround that the source data does not demonstrate.
  • Whale 13F Flow (13 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying holder detail is not provided in the source data, so the drivers of this score cannot be verified here. Investor implication: institutional interest is a partial offset, but it is not strong enough to lift the composite score.
  • Insider Conviction (6 / 20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data. Investor implication: insider signals are weak in the composite, reducing confidence in management's own view of near-term value.
  • Macro Regime Fit (8 / 20): Per the RQD rating, beta is 1.07 and the score reflects sector sensitivity. Investor implication: the stock tends to move roughly in line with the market, with no defensive cushion from its macro profile.
  • Forensic Balance Sheet (5 / 20): Per the RQD rating, Altman Z is 0.45, Piotroski F is 5/9, and Debt/Equity is 1.27. Investor implication: the low Altman Z is in the distress-risk range, and leverage is high relative to equity. This is the most significant constraint on the thesis.

Valuation tradeoff: The forward P/E of 21 is per the market data section. Against trailing EPS of -11.84, the stock is priced on expected recovery rather than current earnings. A prospective investor is therefore underwriting a turnaround, not paying for demonstrated profitability.

Business

Acadia Healthcare Company Inc. is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry, per the company profile. The profile does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $3312.8M for FY 2025, indicating a substantial operating scale. The specific mechanics of how it earns that revenue are not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$3312.8M$-1301.3M$-1102.8MN/A$-439.9M$133.2M$2471.5M
FY 2024$3154.0M$301.6M$255.6MN/A$-560.7M$76.3M$1880.1M
FY 2023$2928.7M$-25.6M$-21.7MN/A$330.5MN/A$822.4M

Per the SEC financials, revenue grew from $2928.7M in FY 2023 to $3312.8M in FY 2025, but FY 2025 operating income swung to $-1301.3M and net income to $-1102.8M. Market data shows an operating margin of -40.6% and a net margin of -33.3%, and ROIC of -24.8%. The Altman Z-Score of 0.45 and Piotroski F-Score of 5/9 are per the RQD rating. Debt rose from $822.4M in FY 2023 to $2471.5M in FY 2025 against cash of $133.2M, a balance sheet posture the RQD rating classifies as vulnerable.

Recent Catalysts & News Wire Analysis

The news wire contains six headlines, all tagged to ACHC, from Yahoo Finance, TradingView, Simply Wall St, and Stock Traders Daily. Two are tagged GREEN with a CATALYST impact label: "Acadia Healthcare Company (ACHC) Could Be 11% Undervalued On Its Growth Narrative" and "Acadia Healthcare Company (ACHC) Rebounds Sharply, Is The Stock Still A Bargain?" Four are tagged YELLOW with MARKET WIRE labels, including "Acadia Healthcare (ACHC) Stock May Be Below Fair Value On Sales" and "Acadia Healthcare (ACHC): Buy, Sell, or Hold Post Q2 Earnings?" The feed summaries are generic and do not describe specific catalyst content, so the substance of the growth narrative or the Q2 results is not available in source data. Risk watch: the headlines' valuation framing ("below fair value," "undervalued") conflicts with the negative RQD composite, and the source data does not reconcile the two. Proprietary signals from the Butterfly Supply-Chain Graph: none.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are therefore not available in source data. The only sector-level input is beta of 1.07 and the Health Care / Medical Specialities classification.

Open Questions

  • What drove the swing from FY 2024 net income of $255.6M to FY 2025 net loss of $-1102.8M, and is it recurring or one-time?
  • What is the composition of the $2471.5M debt, its maturity schedule, and its interest cost?
  • What specific institutional, options, and insider transactions underlie the 13 and 6 pillar scores?
  • Do the "undervalued" headlines rest on a sales-based or growth-based model, and what assumptions do they use?
  • Why is FY 2023 cash listed as N/A and EPS as N/A across all periods?

ACHC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Acadia Healthcare Company Inc. (ACHC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACHC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACHC Bull vs. Bear Conversation Board — What's Your Call at $29.96?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACHC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ACHC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $25.92 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ACHC (D- • RQD 37/100) a Buy at $29.46?

Welcome to the ACHC (Acadia Healthcare Company Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $23.27 (-21.0%)
Spot @ $29.46

Pump the brakes on ACHC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ACHC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Acadia Healthcare Company Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $33.58 (+14.0%)
Spot @ $29.46

ACHC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ACHC, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $29.46 (52-wk range $11.43 - $35.83), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%